Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Craneware full-year revenue set to top expectations

(Sharecast News) - US healthcare management and support specialist Craneware reported a strong full-year sales performance in an update on Thursday, driven by ongoing investment in the Trisus platform and successful partner programmes, resulting in significant returns for its US healthcare provider customers. The AIM-traded firm said it expected revenue to exceed $188m for the 12 months ended 30 June, surpassing the upper end of current market expectations and marking an 8% increase over the prior year.

It also anticipated delivering an adjusted EBITDA of at least $58m, a 6% increase from 2023's $54.9m, maintaining an above-30% EBITDA margin.

The company said it saw growth in annual recurring revenue (ARR), reaching $172m as of 30 June, up from $169m the previous year.

That growth was expected to continue as more sales and partner successes converted to ARR.

Craneware said its strong cash generation enabled continued investment in its future while also significantly reducing its total bank debt to $35.4m, a $40m reduction beyond normal scheduled repayments from 2023's $83m.

It said it returned $12.8m to shareholders through dividends, up from $12.1m in the 2023 financial year, and completed $3.3m in share purchases via its share buyback programme and the employee benefit trust.

Additionally, Craneware said it retained healthy cash reserves of $34.6m as of 30 June, down from $78.5m a year earlier.

Looking ahead, the firm said its strong sales performance underscored the robustness of its Trisus platform, increasing partner success, and its unique market position.

The company said its range of solutions and new market opportunities, accelerated innovation, and exploration of AI-based applications - bolstered by a recently-announced alliance with Microsoft - positioned it to provide valuable insights to its customers.

"The drive for better value in healthcare continues to dominate strategic priorities within the US healthcare market," said chief executive officer Keith Neilson.

"Our positive financial results reflect the demonstrable impact the Craneware Group can make, in helping our customers meet these priorities.

"The exciting growth and expansion opportunities that our new alliance with Microsoft brings to the group, combined with our continued investment in the Trisus platform, the considerable data assets we maintain, and our independence within the US healthcare market mean we are uniquely placed to support all US hospitals."

Craneware said it would announce its results for the year ended 30 June on 3 September.

At 1330 BST, shares in Craneware were up 1.41% at 2,444p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

Mike Ashley's Frasers Group lifts Asos stake
(Sharecast News) - Mike Ashley's Frasers Group lifted its stake in Asos on Friday to 25.13% from 24.21%.
Caledonia Mining full-year results delayed to end of March
(Sharecast News) - Caledonia Mining said on Friday that the publication of its audited financial results for the year ended 31 December would be delayed due to an accounting query raised by its auditors regarding the treatment of deferred tax dating back to 2019.
Zinc Media to make £0.4m payout to The Edge vendors
(Sharecast News) - Zinc Media Group announced on Friday that it will make a £0.4m earnout payment to the vendors of The Edge Picture Co following the subsidiary's strong trading performance and the achievement of earnings targets set out in the original acquisition terms.
Carnival posts record Q1 revenues, boosts FY earnings outlook
(Sharecast News) - Cruise operator Carnival lifted its full-year earnings outlook on Friday as it reported record revenues for the first quarter, citing outperformance across the board.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.